- Report
- January 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- March 2025
- 136 Pages
Global
From €4666EUR$4,995USD£3,948GBP
- Report
- November 2022
- 150 Pages
Global
From €4531EUR$4,850USD£3,833GBP
- Report
- December 2023
- 165 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Clinical Trials
- January 2024
- 70 Pages
Global
From €1868EUR$2,000USD£1,581GBP
- Report
- January 2024
- 120 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- August 2024
- 91 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- May 2022
- 35 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- May 2022
- 36 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- May 2022
- 41 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- May 2022
- 36 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- November 2021
- 284 Pages
Global
From €2803EUR$3,000USD£2,371GBP
- Book
- August 2019
- 416 Pages

Phosphodiesterase (PDE) is a class of enzymes that catalyze the hydrolysis of phosphodiester bonds. They are involved in a variety of physiological processes, including signal transduction, metabolism, and cell division. In the pharmaceutical industry, PDE inhibitors are used to treat a variety of conditions, including erectile dysfunction, pulmonary hypertension, and asthma. PDE inhibitors work by blocking the action of the enzyme, allowing for increased levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This can lead to increased blood flow, relaxation of smooth muscle, and improved airway function.
Some companies in the PDE market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more